PT2201376E - Um novo biomarcador para monitorizar o desenvolvimento de doenças e avaliar a eficácia de tratamentos - Google Patents

Um novo biomarcador para monitorizar o desenvolvimento de doenças e avaliar a eficácia de tratamentos Download PDF

Info

Publication number
PT2201376E
PT2201376E PT08842581T PT08842581T PT2201376E PT 2201376 E PT2201376 E PT 2201376E PT 08842581 T PT08842581 T PT 08842581T PT 08842581 T PT08842581 T PT 08842581T PT 2201376 E PT2201376 E PT 2201376E
Authority
PT
Portugal
Prior art keywords
disease
activity
inflammatory
quot
cancer
Prior art date
Application number
PT08842581T
Other languages
English (en)
Portuguese (pt)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of PT2201376E publication Critical patent/PT2201376E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
PT08842581T 2007-10-24 2008-10-15 Um novo biomarcador para monitorizar o desenvolvimento de doenças e avaliar a eficácia de tratamentos PT2201376E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin

Publications (1)

Publication Number Publication Date
PT2201376E true PT2201376E (pt) 2012-08-20

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
PT08842581T PT2201376E (pt) 2007-10-24 2008-10-15 Um novo biomarcador para monitorizar o desenvolvimento de doenças e avaliar a eficácia de tratamentos
PT12002502T PT2503338E (pt) 2007-10-24 2008-10-15 Cd73 para monitorizar o desenvolvimento de doenças e avaliar a eficácia de terapias

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT12002502T PT2503338E (pt) 2007-10-24 2008-10-15 Cd73 para monitorizar o desenvolvimento de doenças e avaliar a eficácia de terapias

Country Status (14)

Country Link
US (1) US20100209942A1 (https=)
EP (2) EP2201376B1 (https=)
JP (2) JP4982610B2 (https=)
KR (2) KR20100059902A (https=)
CA (1) CA2702635A1 (https=)
CY (2) CY1113403T1 (https=)
DK (2) DK2201376T3 (https=)
ES (2) ES2532361T3 (https=)
FI (1) FI20070795A0 (https=)
HR (2) HRP20120743T1 (https=)
PL (2) PL2201376T3 (https=)
PT (2) PT2201376E (https=)
SI (2) SI2201376T1 (https=)
WO (1) WO2009053523A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2240781T3 (en) 2008-01-18 2018-03-26 Harvard College METHODS FOR DETECTING DISEASE OR STATE SIGNATURES IN BODY FLUIDS
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
EP2596349B1 (en) 2010-07-23 2017-12-13 President and Fellows of Harvard College Methods of detecting cardiovascular diseases or conditions
EP2596134B1 (en) 2010-07-23 2020-04-08 President and Fellows of Harvard College Methods of detecting diseases or conditions using phagocytic cells
WO2012012693A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
WO2013188846A1 (en) 2012-06-15 2013-12-19 Harry Stylli Methods of detecting diseases or conditions
EP2861788B1 (en) 2012-06-15 2018-10-10 Progenity, Inc. Methods of detecting diseases or conditions using circulating diseased cells
DK2956772T3 (en) * 2013-02-14 2018-08-13 Faron Pharmaceuticals Oy A PROCEDURE FOR DETERMINING ACUTE LUNG FAILURE (ARDS) RELATED BIOMARKERS, A PROCEDURE FOR MONITORING DEVELOPMENT AND TREATMENT OF ARDS BY A PATIENT
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
MA40636A (fr) 2014-09-11 2015-09-11 Colleen Kelly Procédés pour détecter le cancer de la prostate
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
GB201706747D0 (en) 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2228970A1 (en) * 1995-08-18 1997-02-27 Donald W. Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
AU7310496A (en) * 1995-10-13 1997-04-30 Imperial College Of Science, Technology And Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) * 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
US20030099608A1 (en) * 2001-03-27 2003-05-29 Presnell Scott R. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
WO2004084933A1 (en) * 2003-03-28 2004-10-07 Faron Pharmaceuticals Oy Elevation of adenosine level by cytokine-induced expression of cd73
CN1835962A (zh) * 2003-06-03 2006-09-20 加利福尼亚大学董事会 利用乙酰化二糖治疗疾病的组合物与方法
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
WO2007107598A1 (en) * 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
EP3796002B1 (en) * 2006-07-14 2023-11-22 The Regents of The University of California Cancer biomarkers and methods of use thereof

Also Published As

Publication number Publication date
EP2503338A3 (en) 2013-03-13
SI2201376T1 (sl) 2012-09-28
HRP20120743T1 (hr) 2012-10-31
EP2201376A1 (en) 2010-06-30
PL2503338T3 (pl) 2015-06-30
JP2011501176A (ja) 2011-01-06
EP2503338B1 (en) 2014-12-24
CA2702635A1 (en) 2009-04-30
PT2503338E (pt) 2015-03-05
JP2012159514A (ja) 2012-08-23
SI2503338T1 (sl) 2015-06-30
CY1116089T1 (el) 2017-02-08
FI20070795A0 (fi) 2007-10-24
JP4982610B2 (ja) 2012-07-25
HRP20150181T1 (hr) 2015-06-19
DK2503338T3 (en) 2015-03-09
CY1113403T1 (el) 2016-06-22
US20100209942A1 (en) 2010-08-19
KR20100059902A (ko) 2010-06-04
KR20160029869A (ko) 2016-03-15
ES2389751T3 (es) 2012-10-31
EP2503338A2 (en) 2012-09-26
PL2201376T3 (pl) 2013-01-31
WO2009053523A1 (en) 2009-04-30
EP2201376A4 (en) 2011-03-23
EP2201376B1 (en) 2012-08-08
ES2532361T3 (es) 2015-03-26
JP5619810B2 (ja) 2014-11-05
DK2201376T3 (da) 2012-10-15

Similar Documents

Publication Publication Date Title
PT2201376E (pt) Um novo biomarcador para monitorizar o desenvolvimento de doenças e avaliar a eficácia de tratamentos
Sood et al. Adiponectin, leptin, and resistin in asthma: basic mechanisms through population studies
Liu et al. Sirt3 attenuates post-infarction cardiac injury via inhibiting mitochondrial fission and normalization of AMPK-Drp1 pathways
Wu et al. S100a8/a9 contributes to sepsis-induced cardiomyopathy by activating ERK1/2-Drp1-mediated mitochondrial fission and respiratory dysfunction
Léguillette et al. Myosin, transgelin, and myosin light chain kinase: expression and function in asthma
Schoeman et al. Serum cortisol and thyroxine concentrations as predictors of death in critically ill puppies with parvoviral diarrhea
US8975081B2 (en) Biomarker for monitoring development of diseases and assessing the efficacy of therapies
ES2774967T3 (es) IGFBP7 para la predicción del riesgo de LRA cuando se mide antes de una intervención quirúrgica
Tsokos Postmortem diagnosis of sepsis
ES2911270T3 (es) Composición para diagnosticar enfermedades infecciosas o complicaciones infecciosas mediante el uso de triptofanil-arnt sintetasa y método para detectar el marcador de diagnóstico
Taguchi et al. IL-22 is secreted by proximal tubule cells and regulates DNA damage response and cell death in acute kidney injury
Lee et al. Raftlin: a new biomarker in human sepsis
Gamil et al. Increased serum levels of asymmetric dimethylarginine and symmetric dimethylarginine and decreased levels of arginine in Sudanese patients with essential hypertension
ES2353835T3 (es) Biomarcadores para evaluar la función hepática.
Saadoun et al. Serum visfatin as a diagnostic marker of active inflammatory bowel disease.
Olteanu et al. Increased Na+/H+ exchanger activity on the apical surface of a cilium-deficient cortical collecting duct principal cell model of polycystic kidney disease
Ding et al. A pilot study on human circulating system indicated that regenerating islet-derived protein 3 gamma (REG3A) is a potential prognostic biomarker for sepsis
Heuberger et al. The Angiopoietin-2/Angiopoietin-1 ratio increases early in burn patients and predicts mortality
Liu et al. Nuclear factor erythroid 2-related factor 2 potentiates the generation of inflammatory cytokines by intestinal epithelial cells during hyperoxia by inducing the expression of interleukin 17D
Wątek et al. Hypogelsolinemia in patients diagnosed with acute myeloid leukemia at initial stage of sepsis
ES2775178T3 (es) Uso de nucleosomas libres de células como biomarcadores en muestras fecales
Nishino Hypocretin measurements in the CSF, and blood and brain tissue: basic and clinical applications
Jia et al. Lactate dehydrogenase B deficiency-dependent hyperlactatemia coordinates with necroptosis to worsen septic liver and kidney injuries
JP5164567B2 (ja) 慢性副鼻腔炎の重症度および再発性の検査方法
Sumi et al. Regional variations in allergen-induced airway inflammation corresponds to changes in soluble guanylyl cyclase heme and expression of heme-oxygenase-1